These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22336170)

  • 1. [Study of EML4-ALK fusion gene as a biomarker in non-small cell lung cancer].
    Wang L; Wang YH; Liu CY; Han M; Zhang SP; Lai RS
    Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):788-90. PubMed ID: 22336170
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].
    Zhang HJ; Zhang XT; Zhang L
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):862-4. PubMed ID: 23324244
    [No Abstract]   [Full Text] [Related]  

  • 3. Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
    Crystal AS; Shaw AT
    Clin Cancer Res; 2012 Sep; 18(17):4479-81. PubMed ID: 22912388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.
    Watanabe N; Nakahara Y; Taniguchi H; Kimura T; Kondoh Y; Kataoka K; Sakamoto K
    Acta Oncol; 2014 Jan; 53(1):158-60. PubMed ID: 23750540
    [No Abstract]   [Full Text] [Related]  

  • 6. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
    Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
    Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New targets in advanced NSCLC: EML4-ALK.
    Crystal AS; Shaw AT
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
    Tanizaki J; Okamoto I; Okabe T; Sakai K; Tanaka K; Hayashi H; Kaneda H; Takezawa K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Nakagawa K
    Clin Cancer Res; 2012 Nov; 18(22):6219-26. PubMed ID: 22843788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.
    Robesova B; Bajerova M; Hausnerova J; Skrickova J; Tomiskova M; Dvorakova D
    Lung Cancer; 2015 Mar; 87(3):318-20. PubMed ID: 25601488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
    Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
    J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT; Solomon B
    Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.
    Asai N; Yamaguchi E; Kubo A
    Clin Lung Cancer; 2014 May; 15(3):e33-5. PubMed ID: 24702855
    [No Abstract]   [Full Text] [Related]  

  • 15. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic Brain Metastases in NSCLC Harboring the EML4-ALK Translocation after Treatment with Crizotinib.
    Saraceni C; Li PM; Gainor JF; Stopyra GA; Friedman EL
    J Thorac Oncol; 2015 Jul; 10(7):1116-7. PubMed ID: 26134230
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.
    Tamiya A; Okamoto I; Miyazaki M; Shimizu S; Kitaichi M; Nakagawa K
    J Clin Oncol; 2013 Jan; 31(1):e15-7. PubMed ID: 23169500
    [No Abstract]   [Full Text] [Related]  

  • 18. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement.
    Maillet D; Martel-Lafay I; Arpin D; Pérol M
    J Thorac Oncol; 2013 Apr; 8(4):e30-1. PubMed ID: 23486270
    [No Abstract]   [Full Text] [Related]  

  • 19. Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation.
    Tufman AL; Edelmann M; Gamarra F; Reu S; Borgmeier A; Schrödl K; Zauber R; Müller-Lisse U; Huber RM
    J Thorac Oncol; 2014 Jan; 9(1):109-13. PubMed ID: 24346098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
    Djalalov S; Beca J; Hoch JS; Krahn M; Tsao MS; Cutz JC; Leighl NB
    J Clin Oncol; 2014 Apr; 32(10):1012-9. PubMed ID: 24567430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.